VBC Proudly Joins the African Vaccine Manufacturing Initiative (AVMI)
Vaccines and Biotechnology City (VBC) is exceptionally proud to announce our official membership with the African Vaccine Manufacturing Initiative (AVMI). This milestone marks a significant step forward in our mission to champion public health and biotechnology innovation across the continent.
A Strategic Commitment to Health Security This partnership represents far more than just a membership; it is a strategic commitment to intensifying our regional engagement with fellow African manufacturers, researchers, and public health stakeholders. By aligning with AVMI, VBC is directly supporting the African Union’s critical goals for continental health security. We recognize that true health resilience relies on local capacity, which is why we are dedicated to driving the African Union’s vision of achieving comprehensive self-reliance in vaccine development and mass production.
Driving Collaborative Impact Through our active participation in AVMI, VBC aims to strengthen the continental healthcare ecosystem by focusing on:
-
Knowledge Exchange & Tech Transfer: Sharing vital expertise and advanced manufacturing techniques to elevate the continent’s overall biopharmaceutical capabilities.
-
Supply Chain Resilience: Collaborating to build robust, localized supply chains that mitigate the risks of global shortages and ensure equitable access to life-saving human and veterinary vaccines.
-
Unified Innovation: Working alongside regional partners under the “One Health” approach to address comprehensive health challenges efficiently.
The vulnerabilities of global supply chains have highlighted the urgent need for a robust, unified African healthcare infrastructure. The future of African health is not a distant goal—it is being actively built right now. With our state-of-the-art facilities and dedicated expertise, VBC is fully equipped, mobilized, and ready to contribute to a secure, self-reliant Africa.
